FDA Device Intelligence
HomeORGANOGENESIS INC. › TransCyte

TransCyte

ORGANOGENESIS INC. · Model 10633 · UDI-DI 00618474000046

MGR Prescription
0
510(k) clearances
220
Adverse events (55 deaths)
7
Recalls
6
Facilities

Description

TRANSCYTE® is a human fibroblast-derived temporary skin substitute consisting of a polymer membrane and donated neonatal human fibroblast cells cultured under aseptic conditions in vitro on a nylon mesh. Prior to cell growth, this nylon mesh is coated with porcine dermal collagen and bonded to a polymer membrane (silicone). This membrane provides a transparent synthetic epidermis when applied. As fibroblasts proliferate within the nylon mesh, they secrete human dermal collagen, matrix proteins and growth factors. Following freezing, no cellular metabolic activity remains; however, the tissue matrix and bound growth factors are left intact. The human fibroblast-derived temporary skin substitute provides a temporary protective barrier. TRANSCYTE is transparent and allows direct visual monitoring of the wound bed.

Recalls

DateFirmReason
2011-02-21Organogenesis, Inc.Product sterility may be compromised
2011-01-30Organogenesis, Inc.Product sterility compromised
2010-08-02Organogenesis, Inc.Product is contaminated with a yeast identified as Pseudozyma antarctica.
2009-09-27Organogenesis, Inc.Unit contaminated with Staphylococcus epidermidis
2007-12-26Organogenesis, Inc.Contamination: Apligraf units were reported to have contamination in the agarose nutrient medium of some units retained at Organogenesis. Preliminary tests show a gram negative r
2006-09-29Organogenesis, Inc.Product pH out of specification
2003-05-02Smith and Nephew Wound Management (La Jolla)Did not meet finished device specifications for the DNA criteria.

Query this across every FDA database — by API.

Linked GUDID · 510(k)/PMA · MAUDE · recalls · establishments. Free tier, no card required.

Get your free API keyRead the docs
Data compiled from public U.S. FDA sources (GUDID, 510(k)/PMA, MAUDE, recalls, establishment registration). Adverse-event reports are unverified and do not establish causation. Informational only — not medical, clinical, or regulatory advice.